(Q34409641)

English

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Stephen L Lowe

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Conrad J Wong

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jennifer Witcher

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Celedon R Gonzales

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gemma L Dickinson

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robert L Bell

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Linda Rorick-Kehn

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

MaryAnn Weller

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Randall R Stoltz

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jane Royalty

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitra Tauscher-Wisniewski

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

26 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

968-978

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Trial watch: opioid receptor blocker shows promise in Phase II depression trial

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Buprenorphine treatment of refractory depression

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Dynorphin, stress, and depression

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Development of κ opioid receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Tiagabine: absence of kinetic or dynamic interactions with ethanol.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Confidence interval criteria for assessment of dose proportionality.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

30 years of dynorphins--new insights on their functions in neuropsychiatric diseases

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.286

21 January 2018

Identifiers

10.1002/JCPH.286

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34409641&oldid=2143286503"